Bruker–JPMorgan Chase: investor conference, 202501 supply service Bruker presents at JP Morgan Healthcare Conference 2025

	Period	2025-01-13
	Region	San Francisco, CA
	Country	United States (USA)
	Predecessor	Bruker–JPMorgan Chase: investor conference, 202401 supply service Bruker presents at JP Morgan Healthcare Conference 2024
	Partner, 1st	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 43rd Annual Healthcare Conference 2025 San Francisco
	Product 2	analytical instrument
	Person	Laukien, Frank H. (Bruker 201204 President + CEO)
	Person 2	Herman, Gerald N. (Bruker Corp 201806– CFO before Interim CFO joined 12/16 as VP + Corp Controller before Parexel)

Bruker Corporation. (1/7/25). "Press Release: Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference". Billerica, MA.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 13th , 2025 at 3:45 PM Pacific Standard Time.

A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com